Osteoarthritis Pain Articles & Analysis: Older
5 articles found
At Regeneus, our patent position is extremely strong which goes hand in hand with our drive for change to improving and developing our technologies to enhance treatment for pain and osteoarthritis. I believe if there is one positive to come out of a tragedy like COVID-19 it is the widespread acceptance of genetic material in mRNA vaccines which are proven and are ...
Graham Vesey to plan, design, and manufacture a range of products to run in rodent models of acute and neuropathic pain. Those preclinical trials produced positive results where we saw reversal of acute and neuropathic pain. ...
Regeneus has built a strong patent portfolio around the combination of the MSCs and the bioactive MSC secretome to ensure we can utilise this science to address key conditions, such as pain and inflammation, where other companies cannot. Disease modifying treatments are not currently available in the market for knee osteoarthritis and many patients suffering ...
For example, I provided the data to support preclinical studies that evaluated Progenza™ for osteoarthritis in rabbits and pain in rats. Currently, my focus is on conducting assurance reviews of data and documentation relating to our technologies before it is transferred to prospective contract manufacturing organizations (CMOs) we may work with. ...
Back pain and osteoarthritis are “leading causes of disability worldwide.”[1] So it is surprising to learn that doctors today are prescribing antidepressants to alleviate the pain associated with these conditions, despite the findings that there are very negative side effects to these drugs including dependence and withdrawal, not to ...